Medical Cannabis Strains: A Guide to Choosing by Chemistry, Not Name (2026)

By James Buddsey · Updated October 14, 2026

No cannabis strain is approved by the FDA to treat any medical condition, and no good evidence shows that one named strain works better than another for a specific illness. What research does support is narrower: certain cannabinoids, especially THC and CBD, have evidence for certain symptoms, and the safest way to choose a product is by its lab-tested THC and CBD content, not its strain name or its indica or sativa label. Talk to a doctor before using cannabis for a health condition.

This guide is for people considering cannabis for health reasons, including medical patients in Washington and Oregon. It summarizes what authoritative sources say, labels the strength of the evidence, and explains how to pick a product more sensibly than by strain name. It is general information and not medical advice.

What Is Actually Approved

The National Cancer Institute’s physician-facing summary on cannabis states that whole cannabis is not FDA-approved for any medical condition. The approved cannabinoid medicines are specific products (NCI PDQ, Cannabis and Cannabinoids):

The NCI also notes that nabiximols (Sativex), a roughly 1:1 THC to CBD extract, is approved in Canada but not in the United States.

Evidence at a Glance

The most-cited review is the 2017 National Academies of Sciences, Engineering, and Medicine report, The Health Effects of Cannabis and Cannabinoids (National Academies, 2017). Its conclusions apply to cannabis or specific cannabinoids and do not name any strain.

The 2017 report is now several years old, and newer trials exist. For specific conditions, see our evidence summaries on epilepsy, multiple sclerosis and cancer, or the broader cannabis research section. Note also that the NCI says clinical trials on medicinal cannabis are limited, and much of the supporting evidence comes from animal studies or patient surveys (NCI).

Why Strain Names Are a Poor Guide

If you want a particular effect, the name on the jar is a shaky predictor. A 2022 analysis of 89,923 lab-tested flower samples from six US states found the indica, hybrid and sativa labels poorly aligned with the samples’ chemistry, and strain names were more consistent but still far from ideal (Smith et al., PLoS One, 2022). Our guide to the difference between sativa and indica explains the details.

Lab testing reliability is another problem. The NCI raises concerns about inflated cannabinoid content and inconsistent THC results (NCI). Treat the numbers on any label as approximate, and prefer licensed stores that test products.

What to Look at Instead: Chemistry

Researchers sort cannabis by its dominant cannabinoids: Type I is THC-dominant, Type II has an intermediate ratio of THC to CBD, and Type III is CBD-dominant (Babaei and Torkamaneh, Plant Genome, 2026). Nearly all commercial flower is THC-dominant (Smith et al., 2022). People who want little intoxication usually look for CBD-rich products. Our strain guides list typical ranges for three well-known ones:

These are typical lab ranges from our guides. Our guides also warn that seed-grown plants vary in their CBD to THC ratio, which is why growers wanting reliable CBD often use tested clones. High CBD products are not risk-free, because the NCI notes that CBD can inhibit certain liver enzymes (cytochrome P450) and may raise or lower the levels of other drugs (NCI).

Many people also choose strains such as Northern Lights or Purple Kush for bedtime. Those are user reports, not clinical findings, and we cannot say they help any condition.

Risks and Side Effects

Cannabis is not harmless, and the risks are best documented for THC-rich products. The National Academies found (National Academies 2017):

• Substantial evidence of a statistical association with increased risk of motor vehicle crashes.
• Substantial evidence of a statistical association with the development of schizophrenia or other psychoses, with the highest risk among the most frequent users.
• Substantial evidence that more frequent use and earlier initiation are linked to problem cannabis use.
• Substantial evidence that long-term smoking is linked to worse respiratory symptoms and more frequent chronic bronchitis.
• Substantial evidence that maternal cannabis smoking is linked to lower birth weight.
• Moderate evidence of impaired learning, memory and attention during acute use, and moderate evidence of overdose injuries in children in states where cannabis is legal.
• Moderate evidence of a small increase in the risk of developing depression.

In an NCI survey of cannabis users, 65% reported adverse effects, including difficulty concentrating and impaired memory (NCI). Start low, avoid driving, and keep products away from children. Our cannabis dosage guide covers safer dosing.

Medical Cannabis in Washington and Oregon

Washington patients can be entered in a state authorization database by a retailer with a medical endorsement and receive a recognition card (RCW 69.51A.210). Oregon runs its own medical program. Check each state’s rules in our Washington and Oregon guides. Federal law still classifies cannabis as illegal; see federal laws. Find licensed shops in Washington and Oregon.

Talk to Your Doctor

Bring your full medication list, since cannabinoids can interact with other drugs. Ask whether an FDA-approved medicine fits your condition first. If you and your clinician decide to try cannabis, ask for a specific THC and CBD target, a starting dose, a plan to track symptoms, and a point at which to stop. Do not use cannabis in place of treatment for a serious illness. Anyone who is pregnant, has a history of psychosis, or has a cannabis use disorder should be especially careful.

Medical Cannabis Strains FAQ

For adults 21+ in legal states. General information, not medical advice. Talk to a doctor before using cannabis for a health condition.